Matthew Caufield
Stock Analyst at H.C. Wainwright
(4.24)
# 1,445
Out of 4,596 analysts
309
Total ratings
40.6%
Success rate
9.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHAT Phathom Pharmaceuticals | Reiterated: Buy | $26 | $8.75 | +197.14% | 21 | Jul 31, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $36 | $10.18 | +253.63% | 33 | Jul 20, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $88 | $59.04 | +49.05% | 10 | Jul 9, 2026 | |
| LENZ LENZ Therapeutics | Reiterated: Buy | $38 | $5.30 | +616.98% | 17 | Jul 7, 2026 | |
| AKBA Akebia Therapeutics | Reiterated: Buy | $6 | $1.32 | +354.55% | 12 | Jul 1, 2026 | |
| ZBIO Zenas BioPharma | Reiterated: Buy | $44 | $31.44 | +39.95% | 15 | Jun 25, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $8 | $3.71 | +115.63% | 35 | Jun 17, 2026 | |
| IMUX Immunic | Reiterated: Buy | $22 | $13.97 | +57.48% | 15 | Jun 8, 2026 | |
| UPB Upstream Bio | Initiated Coverage: Buy | $36 | $6.31 | +470.52% | 1 | Jun 3, 2026 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $56 | $25.52 | +119.44% | 19 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $44 | $22.21 | +98.11% | 9 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $1.54 | +29.87% | 31 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 | $41.58 | +39.49% | 15 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $6.34 | +89.27% | 12 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $4.95 | +263.64% | 7 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 → $8 | $0.70 | +1,042.86% | 12 | Apr 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0261 | - | 10 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.64 | n/a | 20 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $9.60 | n/a | 9 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $9.69 | n/a | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $77.00 | n/a | 5 | Oct 21, 2022 |
Phathom Pharmaceuticals
Jul 31, 2026
Reiterated: Buy
Price Target: $26
Current: $8.75
Upside: +197.14%
4D Molecular Therapeutics
Jul 20, 2026
Reiterated: Buy
Price Target: $36
Current: $10.18
Upside: +253.63%
Tarsus Pharmaceuticals
Jul 9, 2026
Reiterated: Buy
Price Target: $88
Current: $59.04
Upside: +49.05%
LENZ Therapeutics
Jul 7, 2026
Reiterated: Buy
Price Target: $38
Current: $5.30
Upside: +616.98%
Akebia Therapeutics
Jul 1, 2026
Reiterated: Buy
Price Target: $6
Current: $1.32
Upside: +354.55%
Zenas BioPharma
Jun 25, 2026
Reiterated: Buy
Price Target: $44
Current: $31.44
Upside: +39.95%
Opus Genetics
Jun 17, 2026
Reiterated: Buy
Price Target: $8
Current: $3.71
Upside: +115.63%
Immunic
Jun 8, 2026
Reiterated: Buy
Price Target: $22
Current: $13.97
Upside: +57.48%
Upstream Bio
Jun 3, 2026
Initiated Coverage: Buy
Price Target: $36
Current: $6.31
Upside: +470.52%
Mineralys Therapeutics
Jun 1, 2026
Reiterated: Buy
Price Target: $56
Current: $25.52
Upside: +119.44%
May 26, 2026
Maintained: Buy
Price Target: $44
Current: $22.21
Upside: +98.11%
May 11, 2026
Reiterated: Hold
Price Target: $2
Current: $1.54
Upside: +29.87%
May 11, 2026
Reiterated: Buy
Price Target: $58
Current: $41.58
Upside: +39.49%
May 8, 2026
Reiterated: Buy
Price Target: $12
Current: $6.34
Upside: +89.27%
May 1, 2026
Reiterated: Buy
Price Target: $18
Current: $4.95
Upside: +263.64%
Apr 16, 2026
Maintained: Buy
Price Target: $80 → $8
Current: $0.70
Upside: +1,042.86%
Aug 22, 2025
Rated: Hold
Price Target: n/a
Current: $0.0261
Upside: -
May 27, 2025
Rated: Hold
Price Target: n/a
Current: $2.64
Upside: n/a
May 19, 2025
Reiterated: Hold
Price Target: $9
Current: $9.60
Upside: n/a
Oct 29, 2024
Maintained: Buy
Price Target: $39
Current: $9.69
Upside: n/a
Oct 21, 2022
Rated: Hold
Price Target: n/a
Current: $77.00
Upside: n/a